PepGen Q2 2026 earnings: Lower R&D spending narrows the net loss

PepGen (Nasdaq: PEPG) did not report quarterly revenue and posted a Q2 2026 net loss of $17.8 million, or $0.26 per basic and diluted share, versus $23.1 million, or $0.70 per share, a year earlier. The loss narrowed as lower research and development spending reduced total operating expenses, while PepGen ended June with $117.2 million in cash, cash equivalents and marketable securities. The next major clinical milestone is the November data release from the 10 mg/kg FREEDOM2-DM1 cohort.

Core financial results

PepGen’s net loss narrowed by approximately $5.3 million year over year, driven mainly by a $5.9 million reduction in R&D expenses. A $0.9 million increase in general and administrative expenses partly offset that reduction, while net other income increased by approximately $0.3 million.

The company did not explain the reason for the lower R&D expense. As a clinical-stage biotechnology company, PepGen’s spending, cash runway and clinical progress remain more informative than conventional revenue or margin measures.

PGN-EDODM1 clinical progress

The central operating development was continued advancement of PGN-EDODM1 in myotonic dystrophy type 1. The independent Data and Safety Monitoring Board reviewed available safety data and recommended moving FREEDOM2 into its highest-dose cohort while also allowing dose escalation in the open-label extension. The recommendation supports continued study progression but does not establish clinical efficacy.

Six of the eight participants from the original 5 mg/kg FREEDOM2 cohort elected to join the open-label extension. Management said the safety profile observed after several months of repeat dosing supported the dose-escalation decisions, while the upcoming readouts will provide more information on safety and potential clinical benefit.

Cash runway and balance sheet

Cash, cash equivalents and marketable securities totaled $117.2 million on June 30, 2026, compared with $148.5 million on December 31, 2025. That represents a decline of approximately $31.2 million, or 21.0%, over the six-month period.

Based on currently planned operations, management expects existing funds to support the company into the fourth quarter of 2027. The release did not provide quarterly operating cash flow or free cash flow, so the balance-sheet decline should not be treated as a precise measure of second-quarter cash burn.

Total assets declined to $141.4 million from $173.9 million at year-end, while liabilities decreased to $21.9 million from $26.5 million. Stockholders’ equity was $119.5 million, down from $147.4 million.

Lower spending narrowed the loss, while share growth amplified the per-share improvement

PepGen’s absolute net loss narrowed by approximately 22.8%, but its loss per share narrowed by about 62.9%. The difference reflects the much larger weighted-average share count, which increased from 32.7 million to 69.2 million.

Spreading the quarterly loss across more than twice as many weighted-average shares made the per-share comparison improve more sharply than the underlying net loss. PepGen had approximately 69.3 million shares outstanding at the end of the quarter.

Recent insider transactions

The reported six-month insider summary showed 380,055 shares purchased across five transactions and 10,471 shares sold across four transactions, resulting in net purchases of 369,584 shares. The detailed recent records included the following direct sales; the disclosed data did not state why the insiders sold.

The other six entries among the 10 most recent records were stock awards reported with a $0 transaction value: five awards dated February 27, 2026, and one dated December 8, 2025. Share quantities for those awards were not included in the supplied data.

Risks investors should monitor

• Clinical readout risk: The DSMB’s dose-escalation recommendation was based on available safety data and does not demonstrate that PGN-EDODM1 is effective. The November and first-half 2027 readouts are therefore important tests of the program.
• Development and regulatory timing: PepGen’s planned end-of-Phase 2 regulatory discussions depend on results from the second and third FREEDOM2 cohorts. Enrollment, dosing or data delays could push back the registrational timeline.
• Cash-runway sensitivity: The projection that available funds will last into Q4 2027 assumes currently planned operations. Unexpected clinical-development expenses could shorten that runway.
• Higher share count: Weighted-average shares more than doubled year over year, making the improvement in loss per share substantially larger than the improvement in the company’s absolute net loss.

Summary

PepGen reduced its Q2 2026 net loss primarily through lower R&D spending and retained a cash balance that management expects to fund operations into late 2027. The financial improvement was partly magnified on a per-share basis by a much higher share count. Investor attention now shifts to PGN-EDODM1, with 10 mg/kg FREEDOM2 data expected in November and higher-dose results expected in the first half of 2027.